Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms. Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results